Thus, examining MRS in the longer term following concussion may reveal neurometabolic changes
Gel scaffolds of BMP-2-binding peptide amphiphile nanofibers for spinal arthrodesis
The GLP-3 peptide overview examines emerging receptor targets that may further expand the toolkit
Disclosures: Vivian Choi: Nothing to Disclose, Jonathon Winnay: Prime Medicine: Employee, Chaitali Dutta: Prime medicine: Employee, Charitha Guruge: Prime medicine: Employee, Chris Hart: Prime Medicine Inc.: Employee, Daphne Collias: Prime Medicine: Employee, Harpreet Turna: Nothing to Disclose, Celia Chang: Nothing to Disclose, Justin Darcy: Nothing to Disclose, Douglas Scott: Nothing to Disclose, Matt Roy: Nothing to Disclose, Marine Hatit: Nothing to Disclose, Seth Alexander: Prime Medicine: Employee and Shareholder of Prime Medicine, Venubabu Kotikam: Nothing to Disclose, Rowshon Alam: Nothing to Disclose, Mallikarjuna Putta: Nothing to Disclose, Li Lai: Nothing to Disclose, Andrea De Erkenez: Nothing to Disclose, Jacob Stewart-Ornstein: Nothing to Disclose, Luis Santos: Nothing to Disclose, John Hadcock: Nothing to Disclose, Jeremy Duffield: Nothing to Disclose 731 LIVER TRANSPLANTATION FOR METALD RESEMBLES ALD MORE THAN MASLD Smruti Rath 1 Ashish Bibireddy 2 Ishaan Dharia 2 Thomas Schiano 3 Sander Florman 3 Gene Im 3 , 1 Icahn School of Medicine at Mount Sinai, New York, New York, United States, 2 Icahn School of Medicine at Mount Sinai, New York, New York, United States of America, 3 Recanati/Miller Transplantation Institute, Mount Sinai, New York, USA Background: Steatotic liver disease (SLD) is a new nomenclature that includes alcohol-associated cirrhosis (AC), alcohol-associated hepatitis (AH), metabolic dysfunction-associated liver disease (MASLD), and the newly created metabolic and alcohol-associated liver disease (MetALD)
We Are Here to Help You To learn more, check out our full list of FAQs To learn more, check out our full list of FAQs What does GHK-Cu do
Jun 2010;120(6):1274-8
